Methods of treating bladder cancer
The present invention provides methods and compositions for treating bladder cancer, including metastatic bladder cancer and non-muscle-invasive bladder cancer, by administering a composition comprising nanoparticles that comprise mTOR inhibitor and optionally an albumin.
1. A method of treating bladder cancer in an individual, comprising administering to the individual a) an effective amount of a composition comprising nanoparticles comprising a limus drug and an albumin; and b) an effective amount of Bacillus Calmette-Guerin (BCG).
2. The method of claim 1 , wherein the nanoparticle composition is administered intravesicularly.
3. The method of claim 1 , wherein the bladder cancer is non-muscle-invasive bladder cancer.
4. The method of claim 1 , wherein the bladder cancer is refractory to treatment with mitomycin C or interferon.
5. The method of claim 1 , wherein the nanoparticle composition is administered at least once weekly.
6. The method of claim 1 , wherein the dose of the limus drug in the nanoparticle composition is about 5 mg to about 500 mg.
7. The method of claim 6 , wherein the dose of the limus drug in the nanoparticle composition is about 30 mg to about 400 mg.
8. The method of claim 6 , wherein the nanoparticle composition is administered at a volume of about 20 ml to about 150 ml.
9. The method of claim 6 , wherein the nanoparticle composition is administered intravesicularly, and wherein the composition is retained in the bladder for about 30minutes to about 4 hours.
10. The method of claim 1 , wherein the BCG is administered intravesicularly.
11. The method of claim 10 , wherein the BCG is administered at the dose of about 8 mg to about 100 mg.
12. The method of claim 1 , wherein the limus drug is sirolimus.
13. The method of claim 1 , wherein the nanoparticles in the composition have an average diameter of no greater than about 200 nm.
14. The method of claim 1 , wherein the nanoparticles comprise the limus drug coated with albumin.
15. The method of claim 1 , wherein the bladder cancer is urothelial carcinoma.
16. The method of claim 1 , wherein the bladder cancer is a high grade bladder cancer.
17. The method of claim 1 , wherein the individual is human.